Many venture capitalists took to Twitter on Monday night, decrying news that the U.S. Supreme Court appears poised to overturn Roe v. Wade. Soon they'll have a chance to put their money where their mouths are.
Driving the news: Hey Jane, a U.S. telemedicine startup specializing in abortion pills, plans to seek a Series A round later this spring.
What to know: The business model itself isn't novel. This is direct-to-consumer pharmacy, much like Hims or Ro. The difference is that Hey Jane's primary product is politically controversial, and telemedicine sales of abortion pills are either banned or restricted in 19 states.
The product: Over half of all U.S. abortions are now done via medication, with less than a 1% adverse reaction rate. Hey Jane pills are only for medication abortions at 10 weeks or earlier, which usually can be taken without medical supervision.
Big picture: Hey Jane is using abortion pills as its cornerstone offering, but also had expanded into birth control pills, and hopes to build a diversified digital clinic for women's health.
What they're saying: "We're building a platform for the really stigmatized, underserved health needs for people with uteruses," explains company founder and CEO Kiki Freedman, a former Uber project manager who launched Hey Jane after hearing of new abortion restrictions in Missouri.
The bottom line: Hey Jane is a small piece of a giant, divisive national issue that involves health, liberty, politics, law and business. Whether it becomes a bigger player will be up to investors.
Go deeper… Red states crack down on abortion pills
What abortion access would look like if Roe v. Wade is overturned
Oriana Gonzalez and Ashley Gold contributed to the reporting of this story.


Leave a Reply

Your email address will not be published.